An expert from Flagship Pioneering, the venture creation firm behind Moderna and other life science firms, shares the process of founding a company, how they decide whether to partner with companies, the importance of collaboration and how they approach it, and where science is booming in pharma right now.
Lung-I Cheng, vice president of cell and gene therapy (CGT), Cencora (formerly AmerisourceBergen), discusses CGT commercialization strategies, common knowledge gaps, and what he wishes companies knew about commercialization strategies.
In this Pharm Exec Podcast episode, Gerald Kierce, co founder and CEO of Trustible, and Andrew Camino Chung, the company's CTO and co founder, delve into the realm of artificial intelligence, discussing Trustible's mission and its pioneering efforts to ensure ethical AI use, particularly in the pharmaceutical industry, and how it navigates complex AI regulations across the globe.
In this Pharm Exec Podcast episode, Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, discusses the biggest drug pricing challenges today, what companies should consider for drug pricing (from a legal perspective), the status and potential impact of the Inflation Reduction Act, and drug pricing recommendations.
This podcast companion to our roundtable feature explores the transformative power of AI in pharmaceutical marketing, six months after the arrival of ChatGPT.
Sharon Suchotliff, associate principal at ZS and lead for patient centricity, discusses why patient centricity has become a business imperative for life sciences companies. Sharon delves into the measurement of patient centricity, provides examples of how different companies have approached this and ZS’s approach for Patient Outcomes Impact (POI).
Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Senior editor Fran Pollaro chats with Sharlene Jenner, vice president of engagement strategy, Abelson Taylor about the transformative impact and ethical considerations of AI in the pharmaceutical industry, emphasizing its potential in data analysis and marketing, while also highlighting the pioneering work of AI companies in advancing drug discovery.
HBA mentor of the year and director of U.S. public affairs for AbbVie, Jag Dosanjh, divulges in this Pharm Exec Podcast his approach to leadership and how: “If you listen well, you can learn well.”
Senior editor Fran Pollaro and Morten Nielsen, senior partner for the life sciences practice at Wittkieffer, embark on an insightful exploration of trust in the pharmaceutical industry, discussing its measurement, improvement, and critical role in governance, culture, leadership, and organizational structure, while offering practical advice for industry leaders on embedding transparency, inclusion, and accountability into daily operations.
The 2023 Emerging Pharma Leaders share with the Pharmaceutical Executive editors what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more. (This is the audio-only Pharm Exec Podcast episode!)
Torrey Cope, partner, food, drug, and medical device practice, Sidley Austin LLP, reveals current regulatory challenges in the U.S. for drug approvals, how a one-sized-fits-all approach to marketing and global launches no longer works, and when a global launch may be advantageous.
Join host Fran Pollaro as he delves into the world of patient-centric dermatology innovations with Arcutis president and CEO Frank Watanabe in this Pharmaceutical Executive Podcast episode.
Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses her transition from being a physician to working in pharma, new technologies in reproductive health for men and women, as well as access limitations in fertility treatment.
Increasingly clinical pharma and biotech organizations are deciding to commercialize on their own; just as Contract Research Organizations (CROs) transformed clinical trial operations, Contract Commercial Services are transforming commercial operations. Emerging service models offer new options for clinical organizations. In this podcast, Brent Herspiegel, CEO, and Santosh Naik, Partner, Herspiegel Consulting, share the considerations for pharma and biotech organizations when deciding on their commercial path and partner. How Contract Commercial Services can mitigate common launch risks, what we can learn from Herspiegel Consulting’s experience with 100+ pharma product launches.
Two companies team up to combat rare diseases through drug repurposing, which was heavily informed by one doctor’s experience through unconventionally treating his Castleman disease and (ultimately) saving his own life.
Fran Pollaro talks with Cathi Ahearn, senior vice president, worldwide commercial portfolio strategy, Bristol Myers Squibb about impediments and solutions to break down silos in order to get medications in the hands of patients faster.
Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses recruiting talent in pharma, including finding and keeping the right talent, identifying and nurturing talent (students, specifically), and diversity in the workforce.
Fran Pollaro talks with Faruk Capan is the CEO, EVERSANA INTOUCH & Chief Innovation Officer, EVERSANA about the arrival of Chat GPT and generative AI in the public consciousness. This is just the beginning.
Piper Trelstad, PhD, head of CMC, Bill & Melinda Gates Medical Research Institute, shares her experience being a woman in pharma, particularly at the C-suite level, as well as how to have more diversity in the industry.
Fran Pollaro talks with Amanda Powers-Han, chief marketing officer at Greater Than One, a full-experience marketing agency dedicated to healthcare, about what’s trending in early 2023 for pharma media mixes.
In episode 125, Chris Fox, president of Novartis Gene Therapies, shares insights into her work with gene therapies, commercialization challenges, her role at Novartis, and what the team are most excited about in 2023.
Pratap Khedkar, CEO of ZS, a management consulting and technology firm focused on transforming global healthcare, shares his perspective on what 2023 holds for the sales and marketing vertical.
Experts from Karuna Therapeutics discuss current research into schizophrenia as well as psychosis in Alzheimer's disease—including the (lack) of treatment options available for these disorders.
In episode 122, Marcella Milliet Sciorra, Chief Marketing Officer at DeepIntent, discusses Connected TV, or CTV, how it differs from over the top, and how CTV fits into the future of pharmaceutical marketing.
Learn about the evolving cyber-threat landscape affecting the pharmaceutical industry and the recommended approach to addressing those threats.
In episode 121, Nathalie Dompé, co-CEO of Dompé Pharmaceuticals, shares a glimpse into her journey in the pharma industry, her leadership style, the differences in working in leadership in the United States vs. Europe (Italy, specifically), and technologies in the biopharma industry.
Today’s labs are not sufficient to handle tomorrow’s challenges. What will labs in 2030 or 2040 look like? Mikael Hagstroem, CEO at LabVantage Solutions and expert in harnessing data and analytics, discusses the three phases of digital transformation needed to reimagine business models, achieve better performance, and create long-term sustainable advantage. It starts with changing our labs – the technologies, processes, ways of working, and data solutions.
In episode 120, Nico Saraceno, editor of Pharmaceutical Commerce and host of the Pharmaceutical Commerce Podcast, and Andy Studna, associate editor and cohost of the Applied Clinical Trials Podcast, discuss what their respective podcasts offer to listeners, best guests, and more.
Curia is proud to partner with pharma and biotech companies to make new medicines that save lives. In order to be able to do that, Curia needs to be constantly innovating. In this podcast, you will learn from Curia’s VP of Portfolio and Sourcing, James Grabowski, about Curia’s small and large molecules most recent technologies, and capabilities.
